Aileron Treats First Patient With ALRN-6924 In Breast Cancer Setting

Aileron Therapeutics ALRN enrolled the first patients in its Phase 1b clinical trial evaluating ALRN-6924 for bone marrow in patients patients with p53-mutated breast cancer who are being treated with doxorubicin plus cyclophosphamide and docetaxel (AC+D).

Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, said, “The severe toxicity profile of AC+D will enable us to evaluate ALRN-6924's protective effect against multiple chemotherapy-induced toxicities. Moreover, this breast cancer trial may potentially open an additional regulatory opportunity with established precedents for supportive care drug approvals.”

The company has previously presented non-clinical proof of mechanism data demonstrating ALRN-6924, also proof of mechanism data for cell cycle arrest in bone marrow stem cells and hair follicle cells in healthy human volunteers.

Around one million patients are diagnosed with a p53-mutated cancer every year in the United States.

Aileron Therapeutics closed Wednesday’s trading up 3 percent at $0.44

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksHealth CareGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!